Der Internist

, Volume 44, Issue 8, pp 943–950 | Cite as

Kardiovaskuläre Pharmakotherapie im Alter

Schwerpunkt: Gerontopharmakologie
First Online:
  • 49 Downloads

Zusammenfassung

Die Bedeutung der Gerontopharmakologie nimmt im Bereich der Kardiologie stetig zu, da ältere Menschen häufiger an kardiovaskulären Erkrankungen leiden als Jüngere und zudem ein immer höheres Alter erreichen. Pharmakodynamische und pharmakokinetische Veränderungen im Alter erschweren die adäquate Therapie kardiovaskulärer Erkrankungen. Darüber hinaus kann die oftmals praktizierte Polypharmakotherapie zu potenziellen Arzneimittelinteraktionen führen, die, gerade im Alter, gravierende Auswirkungen haben können. Aufgrund der verschiedenen Komorbiditäten des älteren Patienten ist eine leitliniengerechte Therapie oftmals nur bedingt möglich, da der Einsatz von Medikamenten zur Therapie kardiovaskulärer Erkrankungen wie der Hypertonie, der Herzinsuffizienz oder der koronaren Herzerkrankung nicht selten durch unterschiedliche Begleiterkrankungen eingeschränkt wird. Dieser Artikel befasst sich mit der Therapie kardiovaskulärer Erkrankungen im Alter sowie mit den pharmakologischen Besonderheiten der häufig eingesetzten Medikamente.

Schlüsselwörter

Gerontopharmakologie Hypertonie Herzinsuffizienz Koronare Herzerkrankung Alter 

Abstract

Prevalence of cardiovascular diseases increases with advancing age. Moreover, these patients are getting older and older. Therefore, pharmacotherapy of the elderly becomes a major objective in clinical cardiology. Pharmacodynamic and pharmacokinetic changes in the elderly can interfere with a sufficient treatment of cardiovascular diseases and moreover, multiple drug usage is a considerable risk factor of possible drug-drug interactions. Furthermore, treatment of cardiovascular diseases as hypertension, heart failure or coronary heart disease in the elderly according to the international guidelines is often limited due to co-morbidities restricting usage of the appropriate medication. This review addresses both, the treatment of cardiovascular diseases in the elderly and the pharmacological characteristics of frequently used drugs.

Keywords

Pharmacotherapy Elderly Hypertension Heart failure Coronary heart disease 
This is a preview of subscription content, log in to check access.

Literatur

  1. 1.
    Böhm M (2002) Pathophysiologie der Herzinsuffizienz heute. Herz 27: 75–91CrossRefGoogle Scholar
  2. 2.
    Böhm M (1996) Therapie der chronischen Herzinsuffizienz mit β-Rezeptorenblockern. Z Kardiol 85: 11–21Google Scholar
  3. 3.
    Böhm M (2002) Werden Herzglykoside zur Therapie der Herzinsuffizienz noch benötigt? Dtsch Med Wochenschr 127: 2133–2138Google Scholar
  4. 4.
    Böhm M, Erdmann E (1996) Chronische Herzinsuffizienz. In: Erdmann E, Riecker G (Hrsg) Klinische Kardiologie. Springer, Berlin Heidelberg New York, S 751–917Google Scholar
  5. 5.
    Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R (2002) Safety considerations for statins. Curr Opin Lipidol 13: 637–644CrossRefPubMedGoogle Scholar
  6. 6.
    Deutsche Hochdruckliga, Deutsche Hypertonie-Gesellschaft (2001) Leitlinien für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie. Dtsch Med Wochenschr Suppl. 4: S201–S238Google Scholar
  7. 7.
    Erdmann E (1990) Digitalistherapie im Alter. Verh Dtsch Ges Inn Med 96: 258–265PubMedGoogle Scholar
  8. 8.
    Fernandez-Vega F, Abellan J, Sanz de Castro S, Cucalon JM, Maceira B, Gomez de la Camara A (2001) A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension. Int Urol Nephrol 32: 519–523CrossRefPubMedGoogle Scholar
  9. 9.
    Fletcher AE, Palmer AJ, Bulpitt CJ (1994) Cough with angiotensin converting enzyme inhibitors: how much of a problem? J Hypertens Suppl 12: S43–47Google Scholar
  10. 10.
    Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L (2001) Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 14: 27–31PubMedGoogle Scholar
  11. 11.
    Franklin SS, Gustin WT, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D (1997) Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 96: 308–315PubMedGoogle Scholar
  12. 12.
    Franzen D, Metha A, Seifert N, Braun M, Hopp HW (2001) Effects of beta-blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study. Int J Impot Res 13: 348–351Google Scholar
  13. 13.
    Gambassi G, Lapane KL, Sgadari A et al. (2000) Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Arch Intern Med 160: 53–60CrossRefPubMedGoogle Scholar
  14. 14.
    Gottlieb SS, McCarter RJ, Vogel RA (1998) Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339: 489–497CrossRefPubMedGoogle Scholar
  15. 15.
    Gueyffier F, Bulpitt C, Boissel JP et al. (1999) Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 353: 793–796CrossRefPubMedGoogle Scholar
  16. 16.
    Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351: 1755–1762PubMedGoogle Scholar
  17. 17.
    Himmelmann A, Hedner T, Hansson L, O'Donnell CJ, Levy D (1998) Isolated systolic hypertension: an important cardiovascular risk factor. Blood Press 7: 197–207CrossRefPubMedGoogle Scholar
  18. 18.
    Hunt SA, Baker DW, Chin MH et al. (2001) ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Circulation 104: 2996–3007PubMedGoogle Scholar
  19. 19.
    Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, Chalmers TC (1994) Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 121: 355–362PubMedGoogle Scholar
  20. 20.
    Juhlin-Dannfelt A, Astrom H (1979) Influence of beta-adrenoceptor blockade on leg blood flow and lactate release in man. Scand J Clin Lab Invest 39: 179–183PubMedGoogle Scholar
  21. 21.
    Kjekshus J, Pedersen TR (1995) Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 76: 64C–68CPubMedGoogle Scholar
  22. 22.
    Kjeldsen SE, Kolloch RE, Leonetti G et al. (2000) Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study: Hypertension Optimal Treatment. J Hypertens 18: 629–642CrossRefPubMedGoogle Scholar
  23. 23.
    Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM (2002) Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 288: 351–357CrossRefPubMedGoogle Scholar
  24. 24.
    Liu L, Wang JG, Gong L, Liu G, Staessen JA (1998) Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 16: 1823–1829PubMedGoogle Scholar
  25. 25.
    Mancia G, Grassi G (1996) Considerations on current and future trials in hypertension. Blood Press 5: 327–332PubMedGoogle Scholar
  26. 26.
    Mandinov L, Eberli FR, Seiler C, Hess OM (2000) Diastolic heart failure. Cardiovasc Res 45: 813–825PubMedGoogle Scholar
  27. 27.
    Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C (1994) Hypertension in the elderly. Implications and generalizability of randomized trials. JAMA 272: 1932–1938CrossRefPubMedGoogle Scholar
  28. 28.
    Pitt B, Poole-Wilson PA, Segal R et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582–1587PubMedGoogle Scholar
  29. 29.
    Pulignano G, Del Sindaco D, Tavazzi L et al. (2002) Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J 143: 45–55CrossRefPubMedGoogle Scholar
  30. 30.
    Radack K, Deck C (1991) Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 151: 1769–1776CrossRefPubMedGoogle Scholar
  31. 31.
    Remme WJ, Swedberg K (2001) Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22: 1527–1560CrossRefPubMedGoogle Scholar
  32. 32.
    Salpeter S, Ormiston T, Salpeter E (2002) Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev CD002992Google Scholar
  33. 33.
    Salpeter SR, Ormiston TM, Salpeter EE (2002) Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 137: 715–725PubMedGoogle Scholar
  34. 34.
    Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates C (2002) Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev CD003566Google Scholar
  35. 35.
    Scholz H (1988) Behandlung von kardiovaskulären Erkrankungen im Alter. Pharmazeut Z 41: 50–65Google Scholar
  36. 36.
    Schwartz JB (1996) Calcium antagonists in the elderly. A risk-benefit analysis. Drugs Aging 9: 24–36PubMedGoogle Scholar
  37. 37.
    Shepherd J, Blauw GJ, Murphy MB et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623–1630CrossRefPubMedGoogle Scholar
  38. 38.
    Shorr RI, Ray WA, Daugherty JR, Griffin MR (1997) Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 278: 40–43PubMedGoogle Scholar
  39. 39.
    Smith PJ, Talbert RL (1986) Sexual dysfunction with antihypertensive and antipsychotic agents. Clin Pharm 5: 373–384Google Scholar
  40. 40.
    Staessen JA, Fagard R, Thijs L et al. (1997) Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764PubMedGoogle Scholar
  41. 41.
    Stevenson R, Ranjadayalan K, Wilkinson P, Roberts R, Timmis AD (1993) Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. BMJ 307: 349–353PubMedGoogle Scholar
  42. 42.
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349–1357PubMedGoogle Scholar
  43. 43.
    Tomlinson B (1996) Optimal dosage of ACE inhibitors in older patients. Drugs Aging 9: 262–273PubMedGoogle Scholar
  44. 44.
    United Kingdom Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 317: 713–720PubMedGoogle Scholar
  45. 45.
    WHO (1995) Physician Guidelines (for GPs) designed to be translated and distributed worldwide to primary care physicians.Google Scholar
  46. 46.
    Williams D, Feely J (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41: 343–370PubMedGoogle Scholar
  47. 47.
    Yaffe K, Barrett-Connor E, Lin F, Grady D (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59: 378–384CrossRefPubMedGoogle Scholar
  48. 48.
    Zannad F, Alla F, Dousset B, Perez A, Pitt B (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Rales Investigators. Circulation 102: 2700–2706PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Innere Medizin III, Medizinische Klinik und PoliklinikUniversitätskliniken des SaarlandesHomburg
  2. 2.Innere Medizin III, Medizinische Klinik und PoliklinikUniversitätskliniken des SaarlandesHomburg

Personalised recommendations